Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Basic): 2020-2025

Historic EPS (Basic) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $0.00.

  • Xeris Biopharma Holdings' EPS (Basic) rose 103.50% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.10, marking a year-over-year increase of 78.15%. This contributed to the annual value of -$0.37 for FY2024, which is 17.78% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its EPS (Basic) stood at $0.00 for Q3 2025, which was up 138.46% from -$0.01 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EPS (Basic) ranged from a high of $0.00 in Q3 2025 and a low of -$0.44 during Q4 2021.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.09 (2023), whereas its average is -$0.08.
  • Its EPS (Basic) has fluctuated over the past 5 years, first dropped by 22.22% in 2024, then skyrocketed by 103.50% in 2025.
  • Xeris Biopharma Holdings' EPS (Basic) (Quarterly) stood at -$0.44 in 2021, then skyrocketed by 77.27% to -$0.10 in 2022, then increased by 10.00% to -$0.09 in 2023, then skyrocketed by 66.67% to -$0.03 in 2024, then spiked by 103.50% to $0.00 in 2025.
  • Its EPS (Basic) was $0.00 in Q3 2025, compared to -$0.01 in Q2 2025 and -$0.06 in Q1 2025.